Login / Signup

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.

Harry H YoonHaidong DongQian Shi
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • phase ii
  • double blind
  • placebo controlled
  • big data
  • study protocol
  • free survival
  • machine learning